EP-4735449-A1 - TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE

Abstract

The present disclosure relates to compounds of the formula (I): and pharmaceutically acceptable salts thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as inhibitors of APOL 1 and the treatment of non-diabetic kidney disease or focal segmental glomerulosclerosis.

Inventors

• VOLKMANN, ROBERT
• MECHIN, INGRID
• NAIR, ANIL

Assignees

• OmniAB, Inc.

Dates

Publication Date

20260506

Application Date

20240618

Claims (1)

1. WHAT IS CLAIMED IS: 1. A compound of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O or –(C(R 3 ) 2 ) p –; wherein p is zero, one or two; Y is –(C(R 5 ) 2 ) q –R 4 ; q is an integer from zero to four; each R 1 is independently selected from the group consisting of: hydrogen, –halo, –CF 3 , – CF 2 CF 3 , -–OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –C(O)R 9 , –C(O)OR 9 , –OC(O)R 9 , –OR 9 , –OC(O)OR 9 , –OC(O)N(R 9 ) 2, –N(R 9 ) 2 , –NR 9 C(O)R 9 , –NR 9 C(O)OR 9 , –NR 9 C(O)N(R 9 ) 2, –C(O)N(R 9 ) 2 , –SR 9 , – S(O)R 9 , –SO2R 9 , –SO2N(R 9 )2, –N(R 9 )SO2R 9 , –(C1-C6)alkyl, –(C2-C6)alkenyl, –(C2-C6)alkynyl, – (C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 - C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of: –halo, –OH, –CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , (C 1 -C 6 )alkyl, –C(O)(C 1 -C 6 )alkyl, – C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, –OC(O)O(C 1 -C 6 )alkyl, –OC(O)NH 2 ,– OC(O)NH((C 1 -C 6 )alkyl), –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , –NH(C 1 -C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , – NHC(O)(C1-C6)alkyl, –N((C1-C6)alkyl)-C(O)(C1-C6)alkyl, –NHC(O)NH2, –N((C1- C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 - C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , –NHC(O)O(C 1 -C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , – C(O)NH 2 , –C(O)NH((C 1 -C 6 )alkyl), –C(O)N((C 1 -C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, – SO 2 (C 1 -C 6 )alkyl, –SO 2 NH 2 , -SO 2 NH((C 1 -C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 -C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; and m is an integer from zero to four; each R 2 is independently selected from the group consisting of: hydrogen, –halo, –CF 3 , – C(O)N(R 10 ) 2 , –SR 10 , –S(O)R 10 , –SO 2 R 10 , –SO 2 N(R 10 ) 2 , –N(R 10 )SO 2 R 10 , –(C 1 -C 6 )alkyl, –(C 2 - C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 - C 10 )aryl and –(5-12 member)heteroaryl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, – (C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of –halo, –OH, –CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –(C 1 -C 6 )alkyl, –C(O)(C 1 -C 6 )alkyl, –C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, –OC(O)O(C 1 - C 6 )alkyl, –OC(O)NH 2 , –OC(O)NH((C 1 -C 6 )alkyl), –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , –NH(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , –NHC(O)(C 1 -C 6 )alkyl, –N(C 1 -C 6 )alkylC(O)(C 1 -C 6 )alkyl, – NHC(O)NH 2 , –N((C 1 -C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 -C 6 )alkyl) , –N((C 1 - C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , –NHC(O)O(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , –C(O)NH 2 , –C(O)NH((C 1 -C 6 )alkyl), –C(O)N((C 1 - C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl, –SO 2 NH 2 , –SO 2 NH((C 1 - C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 -C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; and n is an integer from zero to four; each R 3 is independently selected from the group consisting of: hydrogen, –OH, –halo, – CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –C(O)R 8 , –C(O)OR 8 , –OC(O)R 8 , –OR 8 , – OC(O)OR 8 , –OC(O)N(R 8 ) 2 , –N(R 8 ) 2 , –NR 8 C(O)R 8 , –NR 8 C(O)OR 8 , –NR 8 C(O)N(R 8 ) 2, – C(O)N(R 8 ) 2 , –SR 8 , –S(O)R 8 , –SO 2 R 8 , –SO 2 N(R 8 ) 2 , –N(R 8 )SO 2 R 8 and –(C 1 -C 6 )alkyl-R 8 ; R 4 is selected from the group consisting of: –C(O)R 6 , –C(O)OR 6 , –C(=N)R 6 , –OC(O)R 6 , –OR 6 , –OC(O)OR 6 , –OC(O)N(R 6 ) 2 , –N(R 6 ) 2 , –NR 6 C(O)R 6 , –NR 6 C(O)N(R 6 ) 2 , –NR 6 C(O)OR 6 , – C(O)N(R 6 ) 2 , –SR 6 , –S(O)R 6 , –SO 2 R 6 , –SO 2 N(R 6 ) 2 , –N(R 6 )SO 2 R 6 , –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 - C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of: –halo, –OH, –CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –CH 2 OH, –CH 2 CH 2 OH, –(C 1 - C 6 )alkyl, –C(O)(C 1 -C 6 )alkyl, –C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, – OC(O)O(C 1 -C 6 )alkyl, –OC(O)NH 2 , –OC(O)NH(C 1 -C 6 )alkyl, –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , – NH(C 1 -C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , –NH(3-13 member)heterocycloalkyl, –NHC(O)(C 1 -C 6 )alkyl, –N(C 1 -C 6 )alkylC(O)(C 1 -C 6 )alkyl, –NHC(O)NH 2 , –N((C 1 -C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 - C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , – NHC(O)O(C 1 -C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , –C(O)NH 2 , –C(O)NH((C 1 - C 6 )alkyl), –C(O)N((C 1 -C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl, – SO 2 NH 2 , –SO 2 NH((C 1 -C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 - C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl and –(3-13 member)heterocycloalkyl may additionally be optionally substituted with =O; each R 5 is independently selected from the group consisting of: hydrogen, –OH, –halo, – CF 3 , –CF 2 CF 3 , -OCF 3 , -OCF 2 CF 3 , –CN, –NO 2 , –(C 1 -C 6 )alkyl-R 7 , –C(O)R 7 , –C(O)OR 7 , – OC(O)R 7 , –OR 7 , –OC(O)OR 7 , –OC(O)N(R 7 ) 2 , –N(R 7 ) 2 , –NR 7 C(O)R 7 , –NR 7 C(O)OR 7 , – NR 7 C(O)N(R 7 ) 2, –C(O)N(R 7 ) 2 , –SR 7 , –S(O)R 7 , –SO 2 R 7 , –SO 2 N(R 7 ) 2 , –N(R 7 )SO 2 R 7 and –(C 1 - C 6 )alkyl-R 7 ; each R 6 is independently selected from the group consisting of: hydrogen, –OH, –(C 1 - C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl; wherein each of said – (C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of –halo, –OH, –CF 3 , – CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –CH 2 OH, –CH 2 CH 2 OH, –(C 1 -C 6 )alkyl, –C(O)(C 1 - C 6 )alkyl, –(C 6 -C 10 )aryl, –C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, – OC(O)O(C 1 -C 6 )alkyl, –OC(O)NH 2 , –OC(O)NH(C 1 -C 6 )alkyl, –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , – NH(C 1 -C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , –NHC(O)(C 1 -C 6 )alkyl, –N(C 1 -C 6 )alkylC(O)(C 1 -C 6 )alkyl, – NHC(O)NH 2 , –N((C 1 -C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 -C 6 )alkyl) , –N((C 1 - C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , –NHC(O)O(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , –C(O)NH 2 , –C(O)NH((C 1 -C 6 )alkyl), –C(O)N((C 1 - C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl, –SO 2 NH 2 , –SO 2 NH((C 1 - C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 -C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl and – (3-13 member)heterocycloalkyl may additionally be optionally substituted with =O; each R 7 is independently selected from the group consisting of: hydrogen, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 - C 10 )aryl and –(5-12 member)heteroaryl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, – (C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and –(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of: –halo, –OH, –CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –(C 1 -C 6 )alkyl, –C(O)(C 1 -C 6 )alkyl, –C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, –OC(O)O(C 1 - C 6 )alkyl, –OC(O)NH 2 , –OC(O)NH(C 1 -C 6 )alkyl, –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , –NH(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , –NHC(O)(C 1 -C 6 )alkyl, –N(C 1 -C 6 )alkylC(O)(C 1 -C 6 )alkyl, – NHC(O)NH 2 , –N((C 1 -C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 -C 6 )alkyl) , –N((C 1 - C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , –NHC(O)O(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , –C(O)NH 2 , –C(O)NH((C 1 -C 6 )alkyl), –C(O)N((C 1 - C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl, –SO 2 NH 2 , –SO 2 NH((C 1 - C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 -C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; each R 8 is independently selected from the group consisting of: hydrogen, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 - C 10 )aryl and –(5-12 member)heteroaryl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, – (C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and ––(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of –halo, –OH, –CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –(C 1 -C 6 )alkyl, –C(O)(C 1 -C 6 )alkyl, –C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, –OC(O)O(C 1 - C 6 )alkyl, –OC(O)NH 2 , –OC(O)NH(C 1 -C 6 )alkyl, –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , –NH(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , –NHC(O)(C 1 -C 6 )alkyl, –N(C 1 -C 6 )alkylC(O)(C 1 -C 6 )alkyl, – NHC(O)NH 2 , –N((C 1 -C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 -C 6 )alkyl) , –N((C 1 - C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , –NHC(O)O(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , –C(O)NH 2 , –C(O)NH((C 1 -C 6 )alkyl), –C(O)N((C 1 - C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl, –SO 2 NH 2 , –SO 2 NH((C 1 - C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 -C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; each R 9 is independently selected from the group consisting of: hydrogen, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 - C 10 )aryl and ––(5-12 member)heteroaryl; wherein each of said –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, – (C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and ––(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of –halo, –OH, –CF 3 , –CF 2 CF 3 , –OCF 3 , –OCF 2 CF 3 , –CN, –NO 2 , –(C 1 -C 6 )alkyl, –C(O)(C 1 -C 6 )alkyl, –C(O)O(C 1 -C 6 )alkyl, –OC(O)(C 1 -C 6 )alkyl, –O(C 1 -C 6 )alkyl, –OC(O)O(C 1 - C 6 )alkyl, –OC(O)NH 2 , –OC(O)NH(C 1 -C 6 )alkyl, –OC(O)N((C 1 -C 6 )alkyl) 2 , –NH 2 , –NH(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl) 2 , –NHC(O)(C 1 -C 6 )alkyl, –N(C 1 -C 6 )alkylC(O)(C 1 -C 6 )alkyl, – NHC(O)NH 2 , –N((C 1 -C 6 )alkyl)C(O)NH 2, –NHC(O)NH((C 1 -C 6 )alkyl) , –N((C 1 - C 6 )alkyl)C(O)NH((C 1 -C 6 )alkyl) , –N((C 1 -C 6 )alkyl)C(O)N((C 1 -C 6 )alkyl) 2 , –NHC(O)O(C 1 - C 6 )alkyl, –N((C 1 -C 6 )alkyl)C(O)O(C 1 -C 6 )alkyl , –C(O)NH 2 , –C(O)NH((C 1 -C 6 )alkyl), –C(O)N((C 1 - C 6 )alkyl) 2 , –S(C 1 -C 6 )alkyl, –S(O)(C 1 -C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl, –SO 2 NH 2 , –SO 2 NH((C 1 - C 6 )alkyl), –SO 2 N((C 1 -C 6 )alkyl) 2 , –NHSO 2 (C 1 -C 6 )alkyl and –N((C 1 -C 6 )alkyl)SO 2 (C 1 -C 6 )alkyl; each R 10 is independently selected from the group consisting of: hydrogen, –halo, –CF 3 , – CN, –NO 2 , –C(O)R 11 , –C(O)OR 11 , –OC(O)R 11 , –OR 11 , –OC(O)OR 11 , –N(R 11 ) 2 , –NR 11 C(O)R 11 , – NR 11 C(O)N(R 11 ) 2, –C(O)N(R 11 ) 2 , –SR 11 , –S(O)R 11 , –SO 2 R 11 , –SO 2 N(R 11 ) 2 , –N(R 11 )SO 2 R 11 , –(C 1 - C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(C 5 -C 10 )cycloalkenyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and ––(5-12 member)heteroaryl; each R 11 is independently selected from the group consisting of: hydrogen, –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(C 5 -C 10 )cycloalkenyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and ––(5-12 member)heteroaryl; wherein each of said – (C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl, –(C 2 -C 6 )alkynyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, –(C 6 -C 10 )aryl and ––(5-12 member)heteroaryl is optionally substituted with 1-3 substituents selected from the group consisting of hydrogen, –OH, –halo, –CF 3 , –CN, – NO 2 , –(C 1 -C 6 )alkyl, –(C 2 -C 6 )alkenyl and –(C 2 -C 6 )alkynyl. 2. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (I’) (I') , or a pharmaceutically acceptable salt thereof. 3. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (I’’): , or a pharmaceutically acceptable salt thereof. 4. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (Ia’): , or a pharmaceutically acceptable salt thereof. 5. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (Ib’): , or a pharmaceutically acceptable salt thereof. 6. The compound of claim 1, wherein the compound of Formula (I) is a compound of Formula (Ic): , or a pharmaceutically acceptable salt thereof. 7. The compound of claim 1, wherein the compound of Formula I is a compound of Formula (Id) , or a pharmaceutically acceptable salt thereof. 8. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 4, wherein X is O. 9. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 3 or 5-6, wherein X is –(C(R 3 ) 2 ) p – and p is 0. 10. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 4 or 5-6, wherein X is –(C(R 3 ) 2 ) p – and p is 1. 11. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 4 or 5-6, wherein X is –(C(R 3 )2)p– and p is 2. 12. The compound or pharmaceutically acceptable salt thereof of any one of claims 9- 11, wherein each R 3 is independently hydrogen. 13. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 12, wherein each R 1 is –halo. 14. The compound or pharmaceutically acceptable salt thereof of claim 12, wherein each R 1 is –fluoro. 15. The compound or pharmaceutically acceptable salt thereof of claim 12 or 13, wherein m is 2. 16. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 15, wherein R 2 is –halo. 17. The compound or pharmaceutically acceptable salt thereof of claim 16, wherein R 2 is –fluoro. 18. The compound or pharmaceutically acceptable salt thereof of claim 16 or 17, wherein n is 1. 20. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –C(O)R 6 . 21. The compound or pharmaceutically acceptable salt thereof of claim 20, wherein R 4 is –C(O)R 6 and R 6 is hydrogen. 22. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –C(O)OR 6 . 23. The compound or pharmaceutically acceptable salt thereof of claim 21, wherein R 4 is –C(O)OR 6 and R 6 is hydrogen or an optionally substituted –(C 1 -C 6 )alkyl. 24. The compound or pharmaceutically acceptable salt thereof of claim 22, wherein R 4 is –C(O)OH or –C(O)OCH 3 . 25. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19,wherein R 4 is –OC(O)R 6 . 26. The compound or pharmaceutically acceptable salt thereof of claim 25,wherein R 4 is –OC(O)R 6 and R 6 is hydrogen or an optionally substituted –(C 1 -C 6 )alkyl. 27. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19,wherein R 4 is –OR 6 . 28. The compound or pharmaceutically acceptable salt thereof of claim 27,wherein R 4 is –OR 6 and R 6 is hydrogen or an optionally substituted –(C 1 -C 6 )alkyl. 29. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19,wherein R 4 is –OC(O)OR 6 . 30. The compound or pharmaceutically acceptable salt thereof of claim 29,wherein R 4 is –OC(O)OR 6 and R 6 is hydrogen or an optionally substituted –(C 1 -C 6 )alkyl. 31. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19,wherein R 4 is –OC(O)N(R 6 ) 2 . 32. The compound or pharmaceutically acceptable salt thereof of claim 31,wherein R 4 is –OC(O)N(R 6 ) 2 and each R 6 is independently selected from the group consisting of hydrogen, – (C 1 -C 6 )alkyl, –(C 3 -C 10 )cycloalkyl and –(3-13 member)heterocycloalkyl, wherein –(C 1 -C 6 )alkyl, – (C 3 -C 10 )cycloalkyl and –(3-13 member)heterocycloalkyl are each optionally substituted. 33. The compound or pharmaceutically acceptable salt thereof of claim 32, wherein R 4 is –OC(O)NH 2 . 34. The compound or pharmaceutically acceptable salt thereof of claim 32, wherein R 4 is –OC(O)NH(R 6 ). 35. The compound or pharmaceutically acceptable salt thereof of claim 34, wherein R 6 is an optionally substituted –(C1-C6)alkyl. 36. The compound or pharmaceutically acceptable salt thereof of claim 35, wherein R 6 is substituted with at least one of –OH, –CH 2 OH or –(C 1 -C 6 )alkyl. 37. The compound or pharmaceutically acceptable salt thereof of claim 34, wherein R 6 is an optionally substituted –(C 3 -C 10 )cycloalkyl. 38. The compound or pharmaceutically acceptable salt thereof of claim 37, wherein R 6 is cyclobutyl substituted with –OH or –CH 2 OH. 39. The compound or pharmaceutically acceptable salt thereof of claim 34, wherein R 6 is an optionally substituted –(3-13 member)heterocycloalkyl. 40. The compound or pharmaceutically acceptable salt thereof of claim 39, wherein R 6 is oxetanyl substituted with –OH or –CH 2 OH. 41. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –N(R 6 ) 2 . 42. The compound or pharmaceutically acceptable salt thereof of claim 41, wherein R 4 is –N(R 6 ) 2 and each R 6 is independently selected from the group consisting of hydrogen, –(C 1 - C 6 )alkyl, –SO 2 (C 1 -C 6 )alkyl and –(3-13 member)heterocycloalkyl, wherein –(C 1 -C 6 )alkyl and –(3- 13 member)heterocycloalkyl are each optionally substituted. 43. The compound or pharmaceutically acceptable salt thereof of claim 41, wherein R 4 is –NH 2 . 44. The compound or pharmaceutically acceptable salt thereof of claim 41, wherein R 4 is –NH(C 1 -C 6 )alkyl, wherein the (C 1 -C 6 )alkyl is optionally substituted. 45. The compound or pharmaceutically acceptable salt thereof of claim 44, wherein the –(C 1 -C 6 )alkyl is substituted with at least one of –OH, –CH 2 OH, –CH 2 CH 2 OH or –C(O)O(C 1 - C 6 )alkyl. 46. The compound or pharmaceutically acceptable salt thereof of claim 41, wherein R 4 is NH(3-13 member)heterocycloalkyl, wherein the –(3-13 member)heterocycloalkyl is optionally substituted. 47. The compound or pharmaceutically acceptable salt thereof of claim 46, wherein the –(3-13 member)heterocycloalkyl is pyrrolidinyl substituted with =O. 48. The compound or pharmaceutically acceptable salt thereof of claim 41, wherein R 4 is –NHSO 2 (C 1 -C 6 )alkyl, wherein (C 1 -C 6 )alkyl is optionally substituted. 49. The compound or pharmaceutically acceptable salt thereof of claim 48, wherein the – (C 1 -C 6 )alkyl is substituted with –OH. 50. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –NR 6 C(O)R 6 . 51. The compound or pharmaceutically acceptable salt thereof of claim 50, wherein R 4 is –NR 6 C(O)R 6 and each R 6 is independently selected from the group consisting of hydrogen, – (C 1 -C 6 )alkyl and –(C 3 -C 10 )cycloalkyl, wherein –(C 1 -C 6 )alkyl and –(3-13 member)heterocycloalkyl are each optionally substituted. 52. The compound or pharmaceutically acceptable salt thereof of claim 51, wherein R 4 is –NHC(O)(C 1 -C 6 )alkyl, wherein the –(C 1 -C 6 )alkyl is optionally substituted. 53. The compound or pharmaceutically acceptable salt thereof of claim 52, wherein the –(C 1 -C 6 )alkyl is substituted with –OH, –CH 2 OH or –NH 2 . 54. The compound or pharmaceutically acceptable salt thereof of claim 51, wherein R 4 is –NHC(O) (3-13 member)heterocycloalkyl, wherein the –(3-13 member)heterocycloalkyl is optionally substituted. 55. The compound or pharmaceutically acceptable salt thereof of claim 54, wherein the –(3-13 member)heterocycloalkyl is optionally substituted oxetanyl. 56. The compound or pharmaceutically acceptable salt thereof of claim 55, wherein oxetanyl is substituted with –OH or –CH 2 OH. 57. The compound or pharmaceutically acceptable salt thereof of claim 54, wherein the –(3-13 member)heterocycloalkyl pyrrolidinyl substituted with =O. 58. The compound or pharmaceutically acceptable salt thereof of claim 51, wherein R 4 is –NHC(O)(C 3 -C 10 )cycloalkyl, wherein the –(C 3 -C 10 )cycloalkyl is optionally substituted. 59. The compound or pharmaceutically acceptable salt thereof of claim 58, wherein the –(C 3 -C 10 )cycloalkyl is cyclopropyl substituted with –OH or –CH 2 OH. 60. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19,wherein R 4 is –NR 6 C(O)N(R 6 ) 2 . 61. The compound or pharmaceutically acceptable salt thereof of claim 60, wherein R 4 is –NR 6 C(O)N(R 6 ) 2 and each R 6 is independently selected from the group consisting of hydrogen, –(C 1 -C 6 )alkyl and –(3-13 member)heterocycloalkyl, wherein –(C 1 -C 6 )alkyl and –(3-13 member)heterocycloalkyl are each optionally substituted. 62. The compound or pharmaceutically acceptable salt thereof of claim 61, wherein R 4 is –NHC(O)NH 2 . 63. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –NR 6 C(O)OR 6 . 64. The compound or pharmaceutically acceptable salt thereof of claim 63, wherein R 4 is –NR 6 C(O)OR 6 and each R 6 is independently hydrogen or an optionally substituted –(C 1 - C 6 )alkyl. 65. The compound or pharmaceutically acceptable salt thereof of claim 64, wherein R 4 is –NHBoc. 66. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –C(O)N(R 6 ) 2 . 67. The compound or pharmaceutically acceptable salt thereof of claim 66, wherein R 4 is –C(O)N(R 6 ) 2 and each R 6 is independently selected from the group consisting of hydrogen, – OH or –O(C 1 -C 6 )alkyl, –(C 1 -C 6 )alkyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl, wherein –(C 1 -C 6 )alkyl, –(C 3 -C 10 )cycloalkyl, –(3-13 member)heterocycloalkyl and –O(C 1 -C 6 )alkyl are each optionally substituted. 68. The compound or pharmaceutically acceptable salt thereof of claim 67, wherein R 4 is –C(O)NH 2 . 69. The compound or pharmaceutically acceptable salt thereof of claim 67, wherein R 4 is –C(O)N(H)OH. 70. The compound or pharmaceutically acceptable salt thereof of claim 67, wherein R 4 is –C(O)N(H)(C 3 -C 10 )cycloalkyl, wherein –(C 3 -C 10 )cycloalkyl is optionally substituted. 71. The compound or pharmaceutically acceptable salt thereof of claim 70, wherein the –(C 3 -C 10 )cycloalkyl is cyclobutyl substituted with –OH or CH 2 OH. 72. The compound or pharmaceutically acceptable salt thereof of claim 67, wherein R 4 is –C(O)N(H)(C 1 -C 6 )alkyl, wherein the –(C 1 -C 6 )alkyl is optionally substituted. 73. The compound or pharmaceutically acceptable salt thereof of claim 72, wherein the –(C 1 -C 6 )alkyl is substituted with at least one of –OH, –CH 2 OH, –NH 2 , –(C 1 -C 6 )alkyl. 74. The compound or pharmaceutically acceptable salt thereof of claim 67, wherein R 4 is –C(O)N(H) (3-13 member)heterocycloalkyl, wherein the –(3-13 member)heterocycloalkyl is optionally substituted. 75. The compound or pharmaceutically acceptable salt thereof of claim 74, wherein the –(3-13 member)heterocycloalkyl is pyrrolidinyl substituted with =O. 76. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19; wherein R 4 is optionally substituted ––(5-12 member)heteroaryl. 77. The compound or pharmaceutically acceptable salt thereof of claim 76, wherein R 4 is selected from the group consisting of pyridyl, pyrimidyl, pyrazolyl, oxadiazolyl, imidazolyl, wherein pyridyl, pyrimidyl, pyrazolyl, oxadiazolyl, and imidazolyl are each optionally substituted. 78. The compound or pharmaceutically acceptable salt thereof of claim 77, wherein R 4 is substituted with –OH, –CH 2 OH, –CF 3 or –NH(3-13 member)heterocycloalkyl, wherein the –(3- 13 member)heterocycloalkyl is optionally further substituted with =O. 79. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is optionally substituted –(3-13 member)heterocycloalkyl. 80. The compound or pharmaceutically acceptable salt thereof of claim 79, wherein R 4 is morpholinyl, oxetanyl, pyrrolidinyl or imidazolidinyl, wherein morpholinyl, oxetanyl, pyrrolidinyl and imidazolidinyl are each optionally substituted. 81. The compound or pharmaceutically acceptable salt thereof of claim 80, wherein oxetanyl is substituted with –OH or –CH 2 OH. 82. The compound or pharmaceutically acceptable salt thereof of claim 80, wherein imidazolidinyl or pyrrolidinyl is substituted with =O. 83. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is optionally substituted –(C 1 -C 6 )alkyl. 84. The compound or pharmaceutically acceptable salt thereof of claim 83, wherein R 4 is substituted with at least one of –CN, –CF 3 , –OH or –CH 2 OH. 85. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is optionally substituted –(C 3 -C 10 )cycloalkyl. 86. The compound or pharmaceutically acceptable salt thereof of claim 85, wherein R 4 is optionally substituted with at least one of –OH, –CH 2 OH, –CH 2 CH 2 OH or –(C 1 -C 6 )alkyl. 87. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –(C 2 -C 6 )alkynyl. 88. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 19, wherein R 4 is –C(=N)R 6 . 89. The compound or pharmaceutically acceptable salt thereof of claim 88, wherein R 6 is –OH. 90. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 89, wherein at least one of R 5 is –OH. 91. The compound or pharmaceutically acceptable salt thereof of any one of claims 1- 90, wherein at least one of R 5 is –halo. 92. The compound or salt of claim 97, wherein the (C 3 -C 10 )cycloalkyl is substituted with at least one of –OH, –CH 2 OH or –CH 2 CH 2 OH. 93. The compound or pharmaceutically acceptable salt thereof of claim 1 wherein said compound is selected from the group consisting of: pharmaceutically acceptable salt thereof. 94. The compound or pharmaceutically acceptable salt thereof of claim 99 wherein said compound is selected from the group consisting of: pharmaceutically acceptable salt thereof. 95. The compound or pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of: , or a pharmaceutically acceptable salt thereof. 96. A pharmaceutical composition comprising a compound or salt of any one of claims 1-95, and a pharmaceutically acceptable carrier. 97. The pharmaceutical composition of claim 96 additionally comprising an antiviral agent. 98. The pharmaceutical composition of claim 97, wherein the antiviral agent is selected from the group consisting of Remdesivir, Nirmatrelvir, Ritonavir, Molnupiravir, Interferon alfa, Interferon lambda and Ivermectin. 99. The use of a compound of any one of claims 1-95, or a pharmaceutically acceptable salt or composition thereof for the manufacture of a medicament to treat a disease for which APOL1 inhibition is indicated. 100. The use of a compound of any one of claims 1-95, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of non-diabetic kidney disease or focal segmental glomerulosclerosis. 101. A method for the treatment of focal segmental glomerulosclerosis in a mammal, including a human, in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of any one of claims 1-95 or a pharmaceutically acceptable salt thereof. 102. A method for the treatment of non-diabetic kidney disease in a mammal, including a human, in need of such treatment comprising administering to said mammal a therapeutically effective amount of a compound of any one of claims 1-95 or a pharmaceutically acceptable salt thereof. 103. A pharmaceutical composition comprising the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt thereof of any one of claims 1 to 95 and a pharmaceutically acceptable carrier. 104. A method of treating focal segmental glomerulosclerosis and/or non-diabetic kidney disease comprising administering to a patient in need thereof the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt of any one of claims 1 to 95. 105. A method of inhibiting APOL1 activity comprising contacting said APOL1 with the compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt of any one of claims 1 to 95. 106. A kit comprising at least two of: (a) compound of Formula I; and (b) an antiviral agent selected from the group consisting of Remdesivir, Nirmatrelvir, Ritonavir, Molnupiravir, Interferon alfa, Interferon lambda, Ivermectin and combinations thereof.

Description

TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Prov. Patent App. No.63/524,176, titled “TETRACYCLIC COMPOUNDS CONTAINING A FUSED INDOLE FOR TREATING APOL1-MEDIATED CHRONIC KIDNEY DISEASE” and filed on June 29, 2023, the disclosure of which is hereby incorporated herein by reference in its entirety. BACKGROUND Field [0002] The present disclosure relates to novel tetracyclic compounds including their pharmaceutically acceptable salts. The disclosure also relates to processes for the preparation of intermediates used in the preparation of pharmaceutical compositions containing such compounds and the uses of such compounds in treating focal segmental glomerulosclerosis including non- diabetic kidney disease. Description of the Related Art [0003] Apolipoprotein L1 (APOL1) genetic coding variants were identified in 2010 and incidence studies since then have demonstrated that such dysfunctional alleles are relatively common among individuals of sub-Saharan African descent. Combined allele frequency of the two common variants G1 and G2 occurs in about 34% of African Americans and have clinically been identified as a frequent cause of kidney disease (termed APOL1 nephropathy) that typically manifests as focal segmental glomerulosclerosis and clinically manifests as hypertension and arterionephrosclerosis. Additional cell culture studies have suggested that APOL1 variants cause cell dysfunction through several processes, including alterations in cation channel activity, inflammasome activation, increased endoplasmic reticulum stress, activation of protein kinase R, mitochondrial dysfunction and disruption of APOL1 ubiquitinylation. Although risk of APOL1 nephropathy is mostly confined to individuals with two APOL1 risk variants, evidence has accumulated that secondary factors elevate the clinical risk for even one allele. The most common secondary factor responsible for clinically relevant kidney disease is a chronic viral infection, particularly HIV-1, resulting in interferon-mediated activation of the APOL1 promoter. See for example, Avi Z. Rosenberg et. al., "The evolving story of apolipoprotein L1 nephropathy: the end of the beginning," Nature Reviews Nephrology, 18, 307–320 (2022). [0004] The clinical pathophysiology of APOL1 has been described by numerous investigators including: David J. Friedman and Martin R. Pollak, "APOL1 Nephropathy: From Genetics to Clinical Applications," CJASN February 2021, 16 (2) 294-303; DOI: https://doi.org/10.2215/CJN.15161219. See also Barry Freedman et al., "APOL1 at ten years: Progress and next steps," Kidney Int.2021 Jun; 99(6): 1296–1302. SUMMARY [0005] The compounds of the present disclosure are inhibitors of apolipoprotein L1 (APOL1) and as such the present disclosure includes methods of using these compounds to treat APOL1-mediated diseases, such as non-diabetic kidney disease (NDKD), focal segmental glomerulosclerosis (FSGS), pancreatic cancer and arterionephrosclerosis, and in treating or ameliorating comorbidities such as hypertension, atherosclerosis, sepsis, sickle cell disease and Covid-19 infection. In some embodiments, the FSGS and/or NDKD is associated with at least one of the 2 common APOL1 genetic variants (G1: S342G:I384M and G2: N388del:Y389del). In some embodiments, pancreatic cancer is associated with elevated levels of APOL1 (such as, e.g., elevated levels of APOL1 in pancreatic cancer tissues). [0006] Some embodiments disclosed herein include a compound having the structure of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O or –(C(R3)2)p–; wherein p is zero, one or two; Y is –(C(R5)2)q–R4; q is an integer from zero to four; each R1 is independently selected from the group consisting of: hydrogen, –halo, –CF3, – CF2CF3, -–OCF3, –OCF2CF3, –CN, –NO2, –C(O)R9, –C(O)OR9, –OC(O)R9, –OR9, –OC(O)OR9, –OC(O)N(R9)2, –N(R9)2, –NR9C(O)R9, –NR9C(O)OR9, –NR9C(O)N(R9)2, –C(O)N(R9)2, –SR9, – S(O)R9, –SO2R9, –SO2N(R9)2, –N(R9)SO2R9, –(C1-C6)alkyl, –(C2-C6)alkenyl, –(C2-C6)alkynyl, – (C3-C10)cycloalkyl, –(3-13 member)heterocycloalkyl, –(C6-C10)aryl and –(5-12 member)heteroaryl; wherein each of said –(C1-C6)alkyl, –(C2-C6)alkenyl, –(C2-C6)alkynyl, –(C3- C10)cycloalkyl, –(3-13 member)heterocycloalkyl, –(C6-C10)aryl and –(5-12 member)heteroaryl is optionally substituted with 1-3 substituents independently selected from the group consisting of: –halo, –OH, –CF3, –CF2CF3, –OCF3, –OCF2CF3, –CN, –NO2, (C1-C6)alkyl, –C(O)(C1-C6)alkyl, – C(O)O(C1-C6)alkyl, –OC(O)(C1-C6)alkyl, –O(C1-C6)alkyl, –OC(O)O(C1-C6)alkyl, –OC(O)NH2,– OC(O)NH((C1-C6)alkyl), –OC(O)N((C1-C6)alkyl)2, –NH2, –NH(C1-C6)alkyl, –N((C1-C6)alkyl)2, – NHC(O)(C1-C6)alkyl, –N((C1-C6)alkyl)-C(O)(C1-C6)alkyl, –NHC(O)NH2, –N((C1- C6)alkyl)C(O)NH2, –NHC(O)NH((C1-C6)alkyl), –N((C1-C6)alkyl)C(O)NH((C1-C6)alkyl), –N((C1- C6)alkyl)C(O)N((C1-C6)alkyl)2, –NHC(O